Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo

被引:18
作者
Bardhan, KD
Cherian, P
Vaishnavi, A
Jones, RB
Thompson, M
Morris, P
Brooks, A
D'Silva, J
Gillon, KRW
Wason, C
Patterson, J
Polak, J
Bishop, A
机构
[1] Rotherham Gen Hosp NHS Trust, Rotherham S60 2UD, S Yorkshire, England
[2] Astra Clin Res Unit, Edinburgh, Midlothian, Scotland
[3] Hammersmith Hosp, Royal Postgrad Med Sch, London, England
关键词
erosive oesophagitis; long term maintenance treatment; omeprazole;
D O I
10.1136/gut.43.4.458
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims-To investigate the efficacy of daily maintenance treatment with omeprazole 10 mg in reducing the relapse rate of healed erosive oesophagitis. Methods-Three hundred patients with erosive oesophagitis (grade 2 or greater) received omeprazole 20 mg daily for 12 weeks, followed by 40 mg daily for a further 12 weeks if required. After healing, patients were randomised to double blind treatment with omeprazole 10 mg daily or placebo for up to 18 months. On relapse the treatment cycle was repeated, Results-The cumulative healing rate at 12 weeks in the initial healing period was 95%, and 96% and 98% on rehealing courses after relapse in the first and second maintenance periods respectively. After 12 weeks of treatment, 98% of patients were free from heartburn and 97% were free of all reflux related symptoms. Relapse in the subgroup of patients who relapsed in both maintenance periods was infrequent an omeprazole 20 mg daily: only 9% at two years, Gastrin concentrations rose above normal in one third of patients. One patient had linear hyperplasia of endocrine cells and another had micronodular hyperplasia. There were no side effects definitely attributable to omeprazole. Conclusion-Maintenance treatment with omeprazole 10 mg daily keeps about 60% of patients with erosive oesophagitis in prolonged remission, Patients relapsing once are likely to do so again; they can subsequently be treated effectively with omeprazole 20 mg daily.
引用
收藏
页码:458 / 464
页数:7
相关论文
共 24 条
  • [1] BARDHAN KD, 1992, FRONT GASTROINTEST R, V20, P246
  • [2] OMEPRAZOLE 10-MG OR 20-MG ONCE-DAILY IN THE PREVENTION OF RECURRENCE OF REFLUX ESOPHAGITIS
    BATE, CM
    BOOTH, SN
    CROWE, JP
    MOUNTFORD, RA
    KEELING, PWN
    HEPWORTHJONES, B
    TAYLOR, MD
    RICHARDSON, PDI
    MCINYRE, PB
    MCFARLAND, RJ
    GREEN, JRB
    THOMPSON, RPH
    ROSE, JDR
    BEVAN, G
    DANESHMEND, TK
    CALAM, J
    OGORMAN, T
    CLARKE, DN
    SHREEVE, DR
    SCHILLER, KF
    KRASNER, N
    FOSTER, DN
    SMITH, PM
    BATESON, MC
    BERESFORD, E
    HEWETT, S
    [J]. GUT, 1995, 36 (04) : 492 - 498
  • [3] BRIANT MG, 1982, RADIOIMMUNOASSAY GUT, P51
  • [4] Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long-term omeprazole trials
    Carlsson, R
    Galmiche, JP
    Dent, J
    Lundell, L
    Frison, L
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (03) : 473 - 482
  • [5] Collet D., 1994, MODELLING SURVIVAL D, V1st
  • [6] INFLUENCE OF THE DEGREE OF SEVERITY OF FUNDIC GASTRITIS ON SERUM GASTRIN-CONCENTRATION AND ECL CELL-DENSITY IN CONTROLS AND DURING PROLONGED TREATMENT WITH ANTISECRETORY DRUGS
    DIEBOLD, MD
    RICHARDSON, S
    ZEITOUN, P
    DUCHATEAU, A
    BIGARD, MA
    COLIN, R
    CORTOT, A
    [J]. GASTROENTEROLOGY, 1995, 108 (04) : A83 - A83
  • [7] CHROMOGRANIN - A NEWLY RECOGNIZED MARKER FOR ENDOCRINE-CELLS OF THE HUMAN GASTROINTESTINAL-TRACT
    FACER, P
    BISHOP, AE
    LLOYD, RV
    WILSON, BS
    HENNESSY, RJ
    POLAK, JM
    [J]. GASTROENTEROLOGY, 1985, 89 (06) : 1366 - 1373
  • [8] GRIMELIUS L, 1968, ACTA SOC MED UPS, V73, P243
  • [9] OMEPRAZOLE OR RANITIDINE IN LONG-TERM TREATMENT OF REFLUX ESOPHAGITIS
    HALLERBACK, B
    UNGE, P
    CARLING, L
    EDWIN, B
    GLISE, H
    HAVU, N
    LYRENAS, E
    LUNDBERG, K
    [J]. GASTROENTEROLOGY, 1994, 107 (05) : 1305 - 1311
  • [10] HEMERY P, 1987, GASTROEN CLIN BIOL, V11, P148